Klaas Bakker, a former executive at AstraZeneca Plc, is to join Oncopeptides AB as chief medical officer in November to help the company manage a global, confirmatory Phase 3 trial of its peptide conjugate melflufen for multiple myeloma. Dr Bakker was most recently vice president for medical affairs at AstraZeneca where he helped manage the commercialisation of the lung cancer treatment Tagrisso. He holds a medical degree and is a board certified neurosurgeon from the University of Groningen in the Netherlands and was clinically active at the university hospital until 2015. He also holds a PhD in immuno-haematology.
Oncopeptides announced the appointment on 20 August 2019.
Copyright 2019 Evernow Publishing Ltd.